Navigation Links
New guidelines for diagnosing, managing and treating Clostridium difficile
Date:3/21/2010

ARLINGTON, VA (March 22, 2010)A joint panel of experts from the Society for Healthcare Epidemiology (SHEA) and the Infectious Diseases Society of America (IDSA) today released online new clinical practice guidelines for Clostridium difficile infection (CDI) in adults. The guidelines, to be published in the May issue of Infection Control and Hospital Epidemiology, update recommendations regarding the epidemiology, diagnosis, treatment and infection control and environmental management of this disease.

CDI is the most commonly recognized cause of infectious diarrhea in healthcare settings and accounts for 20 percent-30 percent of cases of antibiotic-associated diarrhea. The infection manifests itself in a range from symptomless cases to mild or moderate diarrhea to sudden and sometimes fatal colitis. Since publication of guidelines on CDI in 1995, there has been an increase in overall incidence of the infection, a more virulent strain of the infection has been identified, and evidence regarding the decreased effectiveness of a common treatment of the disease has been reported.

"As healthcare professionals and infectious disease experts, we are committed to developing recommendations based on the best available evidence and practices," said Neil Fishman, MD, president of SHEA. "Since our original guideline was published fifteen years ago, our understanding of the epidemiology of CDI has changed, and requires us to update the way we diagnose and treat this serious infection."

The guidelines provide recommendations on the minimum data that should be collected in cases of CDI and how that data should be reported; the best testing strategy to diagnose CDI; the most important infection control measures for a hospital to implement during an outbreak of CDI; and recommendations on the most appropriate drug treatment for patients with CDI.

"The entire infectious disease community is striving toward making our hospitals and healthcare institutions safer for both patients, families and the healthcare professionals who work in them every day," said Rich Whitley, MD, president of IDSA. "The work of this joint panel of the brightest minds in the field demonstrates how closely and seriously we are studying this infection."

While mortality rates associated with CDI have historically been low, occurring in less than 2 percent of cases, the financial burden to the healthcare system has been significant. From 2000 to 2002, annual excess hospital costs in the U.S. for the management of CDI were estimated at $3.2 billion per year.


'/>"/>

Contact: Tamara Moore
tmoore@gymr.com
202-745-5114
Society for Healthcare Epidemiology of America
Source:Eurekalert

Related biology news :

1. NIH stem cell guidelines should be modified, UCSF team reports
2. Pediatrics GI recommendations -- first step to guidelines for children with autism
3. Health Physics Society recommends considering action for indoor radon below current guidelines
4. LSUHSCs England plays key role in developing new ALS treatment guidelines
5. Journal of Vascular and Interventional Radiology: New patient radiation safety guidelines
6. Following the dietary guidelines may slow heart disease in women
7. New guidelines to fight obesity in pregnancy issued
8. Report updates guidelines on how much weight women should gain during pregnancy
9. First comprehensive guidelines for managing medullary thyroid carcinoma published in Thyroid journal
10. Coral Disease Handbook: Guidelines for Assessment, Monitoring and Management
11. Publication sets guidelines across cancer therapies: Ensuring the best in patient management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/3/2017)... Onitor, provider of digital health technology for ... innovative biometric data-driven program designed to aid weight loss ... 2017 Consumer Electronics Show (CES) in Las ... the World Health Organization (WHO), have identified lifestyle risks ... are overweight or obese. WHO also states that more ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016 /PRNewswire/ ... que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que ... de tumor en 2017, con múltiples sitios previstos a lo largo ... ... en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, Inc. ... genomics technology company, announced today that on December 13, ... Department of The Nasdaq Stock Market LLC which acknowledged ... price of WaferGen,s common stock had been at $1.00 ... has regained compliance with Listing Rule 5550(a)(2) of the ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... (PRWEB) , ... January 19, ... ... of advanced software solutions for pharmaceutical research and development (R&D), today announced ... in omic data analysis and interpretation for the rapidly evolving field of ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, ... Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious ... agreement for the merger of PharmAthene and Altimmune ... Novartis Venture Fund, HealthCap, Truffle Capital and Redmont ... and diversified immunotherapeutics company with four clinical stage ...
(Date:1/19/2017)... 19, 2017 AquaBounty Technologies, Inc. (AIM: ABTU; ... in aquaculture and a majority-owned subsidiary of Intrexon Corporation ... completed the listing of its common shares on the ... Intrexon. "AquaBounty,s listing on NASDAQ represents an ... exposure to the U.S. markets as we advance plans ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... innovators, engineers, and scientists from around the world, was today awarded the "Best ... program is based entirely on merit and decided upon by a dedicated team ...
Breaking Biology Technology: